Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Vasopressors in Sepsis
NCT05179499Phase 3Recruiting
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Oct 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of norepinephrine in sepsis and septic shock (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Clinical Effectiveness at 90 days. Started Oct 2022; status: recruiting.
02
Drugs
norepinephrine
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT05179499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179499.